Naveris aims for NavDx to improve treatment selection in patients with HPV-based head and neck cancers. NavDx analyzes tumor-derived DNA from patients’ blood samples to monitor for residual molecular disease, according to an April 12 Naveris news release.
“This clinical trial represents a significant step forward in personalized medicine for head and neck cancer patients,” Piyush Gupta, PhD, founder and CEO of Naveris, said in the release. “NavDx has the potential to be a game-changer in treatment selection, allowing physicians to tailor treatment plans to individual patients based on their unique biomarker profiles.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
